Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has earned an average recommendation of “Buy” from the thirty-one research firms that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation, twenty-five have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $176.90.
Several analysts have recently weighed in on VRTX shares. Royal Bank of Canada assumed coverage on Vertex Pharmaceuticals in a report on Thursday, September 14th. They set an “outperform” rating and a $175.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and issued a $195.00 price objective on shares of Vertex Pharmaceuticals in a research note on Sunday, September 17th. Vetr lowered Vertex Pharmaceuticals to a “sell” rating in a research note on Thursday, September 21st. Zacks Investment Research raised Vertex Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $174.00 price objective on the stock in a research note on Tuesday, September 26th. Finally, BMO Capital Markets reaffirmed a “buy” rating on shares of Vertex Pharmaceuticals in a research note on Wednesday, September 27th.
Vertex Pharmaceuticals (NASDAQ VRTX) traded up $1.02 during trading hours on Monday, hitting $158.40. The stock had a trading volume of 948,500 shares, compared to its average volume of 1,549,514. The company has a market capitalization of $39,910.00, a PE ratio of 203.08, a P/E/G ratio of 1.84 and a beta of 1.58. The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.14 and a current ratio of 3.28. Vertex Pharmaceuticals has a 52 week low of $79.78 and a 52 week high of $167.85.
In other Vertex Pharmaceuticals news, COO Ian F. Smith sold 2,125 shares of the business’s stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $155.61, for a total value of $330,671.25. Following the transaction, the chief operating officer now directly owns 118,013 shares of the company’s stock, valued at $18,364,002.93. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CMO Jeffrey Chodakewitz sold 1,718 shares of the business’s stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $155.19, for a total value of $266,616.42. Following the completion of the transaction, the chief marketing officer now directly owns 116,142 shares in the company, valued at $18,024,076.98. The disclosure for this sale can be found here. Over the last three months, insiders sold 354,214 shares of company stock worth $51,154,692. Insiders own 1.80% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Vertex Pharmaceuticals by 15.4% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 988 shares of the pharmaceutical company’s stock valued at $127,000 after acquiring an additional 132 shares in the last quarter. FNY Partners Fund LP increased its holdings in shares of Vertex Pharmaceuticals by 900.0% during the second quarter. FNY Partners Fund LP now owns 1,000 shares of the pharmaceutical company’s stock valued at $128,000 after acquiring an additional 900 shares in the last quarter. Smithfield Trust Co. bought a new stake in shares of Vertex Pharmaceuticals during the third quarter valued at approximately $135,000. FNY Managed Accounts LLC bought a new stake in shares of Vertex Pharmaceuticals during the third quarter valued at approximately $162,000. Finally, Fuller & Thaler Asset Management Inc. bought a new stake in shares of Vertex Pharmaceuticals during the third quarter valued at approximately $198,000. 93.09% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This article was originally posted by Community Financial News and is the property of of Community Financial News. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.com-unik.info/2018/01/11/analysts-set-vertex-pharmaceuticals-incorporated-vrtx-target-price-at-177-30.html.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
What are top analysts saying about Vertex Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Vertex Pharmaceuticals and related companies.